Focusing on the Diabetes Patient
Published Online: Friday, November 8, 2013
Jonathan G. Marquess, PharmD, CDE, President and CEO of the Institute for Wellness and Education, Inc, explains why he decided to focus on caring for diabetes patients at his pharmacy. This interview was recorded at the National Community Pharmacists Association 115th Annual Convention in Orlando.
The FDA today approved dulaglutide (Trulicity), a once-weekly injectable therapy indicated to improve blood sugar control in adults with type 2 diabetes.
Combined with bolus insulin aspart (NovoLog), insulin degludec (Tresiba) improves long-term glycemic control in children and adolescents with type 1 diabetes.
Results show pharmacists and other healthcare providers can work together to successfully empower patients disproportionately affected by diabetes to achieve improved clinical outcomes.